Cite
HARVARD Citation
Pietrantonio, F. et al. (2016). GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. Journal of translational medicine. 14 (1), pp. 1-7. [Online].